MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.drugalcdep.2020.108221

Медицинская библиотека · Drug and alcohol dependence · 2020

Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial.

Jalali Ali, Ryan Danielle A, Jeng Philip J, McCollister Kathryn E, Leff Jared A, Lee Joshua D, Nunes Edward V, Novo Patricia, Rotrosen John, Schackman Bruce R, Murphy Sean M

Клиническое исследованиеСтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

OBJECTIVE

To examine the health-related quality-of-life (HRQoL) of persons with opioid use disorder (OUD) seeking treatment in an inpatient detoxification or short-term residential setting; continuing treatment as outpatients.

METHODS

We conducted a secondary analysis of data from a clinical trial (N = 508) where participants were randomized to extended-release naltrexone or buprenorphine-naloxone for the prevention of opioid relapse. We used a generalized structural equation regression mixture model to identify associations of HRQoL (EQ-5D) trajectories, including latent characteristics, over the 24-week trial and 36-week follow-up period, among participants who reported HRQoL beyond baseline. This novel framework accounted for baseline and time-varying characteristics, while simultaneously identifying latent classes.

RESULTS

We identified two subpopulations: HRQoL "pharmacotherapy responsive" (82.3 %) and HRQoL "characteristic sensitive" (17.7 %). The pharmacotherapy responsive subpopulation was characterized by a shortterm HRQoL improvement and then stable HRQoL over time, and by a positive association between HRQoL and receiving pharmacotherapy in the past 30 days. The characteristic sensitive subpopulation was characterized by an initial improvement in HRQoL with a gradual decline over time, and no significant HRQoL response to pharmacotherapy. HRQoL changes over time in this subpopulation were more influenced by baseline demographic, socioeconomic, and psychosocial characteristics.

CONCLUSION

Our findings suggest that while HRQoL may be improved and sustained through targeted efforts to promote use of pharmacotherapy for many persons with OUD, an identifiable subpopulation may require additional services that address socioeconomic and psychosocial issues to achieve HRQoL benefits. Our analysis provides insight for improving individualized care for persons with opioid use disorder seeking treatment.

Для цитирования: Jalali Ali, Ryan Danielle A, Jeng Philip J, McCollister Kathryn E, Leff Jared A, Lee Joshua D, Nunes Edward V, Novo Patricia, Rotrosen John, Schackman Bruce R, Murphy Sean M. Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial.. Drug and alcohol dependence. 2020. DOI: 10.1016/j.drugalcdep.2020.108221.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.